The patients are treated with ixazomib (Day1, 8, 15) and lenalidomide (Day1-21) and dexamethasone (Day1, 8, 15, 22) therapy every 28 day cycle for 1 year

Multicenter clinical trials to determine the efficacy and safety of consolidation and maintenance therapy with ixazomib, lenalidomide, dexamethasone (IRd) therapy in transplant-ineligible multiple myeloma.

Multicenter clinical trials to determine the efficacy and safety of consolidation and maintenance therapy with ixazomib, lenalidomide, dexamethasone (IRd) therapy in patients with multiple myeloma after autologous stem cell transplantation.